Bio­phar­ma BD teams are speed­ing in­to the fast lane — cash in hand — as deal­mak­ing con­tin­ues to heat up in Q1 ...

7 years ago
Pharma

Alzheimer’s R&D projects side­lined as Bio­gen’s ad­u­canum­ab shock shakes re­searchers to the core of their be­liefs

7 years ago
Bioregnum
Opinion

Reg­u­la­to­ry in­tel­li­gence: Up­date on re­gen­er­a­tive med­i­cine ad­vanced ther­a­pies des­ig­na­tions

7 years ago
Cell/Gene Tx

What's tak­ing the FTC so long? Roche won't say, but in­sists it will bag Spark on time — de­spite third de­lay

7 years ago
Deals

Sol­id Bio’s high­er gene ther­a­py dose for Duchenne MD runs smack in­to a fresh set of safe­ty is­sues -- shares tum­ble

7 years ago
R&D
Cell/Gene Tx

Min­er­va claims 'pos­i­tive' PhII da­ta on de­pres­sion drug while skep­tics push stock down

7 years ago
R&D

Bi­cy­cle sets terms for $65M IPO; Lil­ly's Cyra­mza wins fifth can­cer ap­proval

7 years ago
News Briefing

Mi­cro­bio­me up­start Vedan­ta gets an ex­tra $18.5M in the bank, wrap­ping up $45.5 Se­ries C round

7 years ago
Financing

Dai­ichi Sankyo faces FDA chal­lenges on miss­ing da­ta, cred­i­bil­i­ty and safe­ty con­cerns in hunt for 2 new drug OKs

7 years ago
R&D
Pharma

‘Too big to care’: Sweep­ing law­suit ac­cus­es Te­va of col­lud­ing with oth­er gener­ic mak­ers to keep prices high

7 years ago
Pharma

They got bounced out of Alex­ion. Now David Hal­lal and Vikas Sin­ha are back with $150M and a fo­cus on cell and gene ...

7 years ago
Financing
Startups

Up­dat­ed: In­ter­change­able biosim­i­lars: FDA fi­nal­izes guid­ance

7 years ago
R&D
FDA+

En­gulfed in le­gal trou­ble, bank­rupt­cy could be the an­swer for opi­oid drug­mak­er In­sys

7 years ago
Pharma

Biotech hits the brakes on their PhI­II piv­otal for a lead an­tibi­ot­ic as in­ves­ti­ga­tors track a high rate of kid­ney ...

7 years ago
R&D

Philo­gen who? A low pro­file but phar­ma-con­nect­ed Ital­ian-Swiss hy­brid steps out with $68M for a fi­nal push over the ...

7 years ago
Financing
R&D

Lam­bast­ed by AIDS ac­tivists about Tru­va­da pric­ing, Gilead of­fers CDC drug sup­ply deal; Fi­bro­Gen MACE mis­com­mu­ni­ca­tion ...

7 years ago
News Briefing

Bi­cy­cle signs on new clin­i­cal ex­ecs in pipeline dri­ve; Howard Stern signs on as Fog­Phar­ma CSO

7 years ago
Peer Review

That feel­ing you get when you hit the fin­ish line, and then set new goals

7 years ago
Editor's note
Bioregnum

Sem­ma goes on a suc­cess­ful ‘fish­ing’ ex­pe­di­tion in its hunt for a di­a­betes cure

7 years ago
R&D

Puma in­vestors fret, as Ner­l­ynx Q1 sales fall un­com­fort­ably short of Wall Street es­ti­mates

7 years ago
Pharma

PhI may still be a killing field of fail­ure but PhI­II suc­cess rates have surged, sig­nal­ing tec­ton­ic shifts in ...

7 years ago
R&D

A new­ly formed biotech launched out of George Da­ley’s Har­vard lab adds glob­al play­ers to its syn­di­cate, bring­ing ...

7 years ago
Startups
R&D

ICER chas­tis­es J&J for over­pric­ing de­pres­sion drug es­ke­t­a­mine ‘where there is such need for treat­ment’

7 years ago
Pharma

Bay­er kicks off a $150M add-on for its cam­pus in Berke­ley

7 years ago
R&D
Cell/Gene Tx
First page Previous page 950951952953954955956 Next page Last page
A service from the Financial Times